GlassScriptPhysician profile
Katherine M Schultz
NPI 1417265323
$1,811.23
in general payments reported to CMS, 2019-2025
19 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $440 · 2024: $1,091 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.34 | 2023-2025 | |
| Novo Nordisk INC | $321.43 | 2023-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $314.11 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $171.91 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.90 | 2023-2024 | Jardiance, Tradjenta, Ofev |
| Pfizer INC. | $65.63 | 2024-2025 | |
| Axsome Therapeutics, INC. | $58.39 | 2023-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $49.05 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Astellas Pharma US INC | $41.40 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $39.24 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $31.45 | 2023-2024 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $27.99 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $26.89 | 2023 | Gardasil 9 |
| Organon LLC | $26.67 | 2024 | |
| Coopersurgical, INC. | $20.59 | 2025 | Paragard T 380a |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $17.41 | 2024 | Belbuca |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2023 | |
| Phadia US INC. | $14.33 | 2025 | Immunocap |
| Amgen INC. | $13.93 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.